

Supplementary Table 1. Prevalence and risk of developing different grades of Systemic and Local Adverse Effects Following Immunisation (S-AEIs and L-AEIs) with MVA-BN Vaccine up to six days from fitting a multinomial logistic regression according to administration route - intradermal (ID) vs subcutaneous (SC).

		Prevalence of S-AEIs and OR (ID vs. SC) up to 6 days from vaccination					
Systemic symptoms	max severity	ID n (%)	SC n (%)	Unadjusted OR (95% CI) ID vs. SC	p-value	Adjusted* OR (95% CI) ID vs. SC	p-value
Fatigue	None	401 (56.0)	137 (60.9)	1	0.001	1	0.856
	Mild	174 (24.3)	35 (15.6)	1.70 (1.13, 2.56)		0.85 (0.37, 1.98)	
	Moderate	106 (14.8)	29 (12.9)	1.25 (0.79, 1.97)		1.41 (0.54, 3.69)	
	Severe	35 (4.9)	24 (10.7)	0.50 (0.29, 0.87)		1.20 (0.38, 3.81)	
Headache	None	500 (69.8)	166 (73.8)	1	0.022	1	0.065
	Mild	152 (21.2)	29 (12.9)	1.74 (1.13, 2.69)		2.66 (1.13, 6.27)	
	Moderate	47 (6.6)	22 (9.8)	0.71 (0.42, 1.21)		0.95 (0.25, 3.67)	
	Severe	17 (2.4)	8 (3.6)	0.71 (0.30, 1.66)		6.60 (0.68, 63.98)	
Myalgia	None	567 (79.2)	172 (76.4)	1	0.811	1	0.970
	Mild	92 (12.8)	32 (14.2)	0.87 (0.56, 1.35)		1.03 (0.39, 2.72)	
	Moderate	38 (5.3)	13 (5.8)	0.89 (0.46, 1.70)		1.11 (0.26, 4.73)	
	Severe	19 (2.7)	8 (3.6)	0.72 (0.31, 1.67)		1.47 (0.31, 6.94)	
Nausea	None	646 (90.2)	199 (88.4)	1	0.176	1	0.895
	Mild	49 (6.8)	15 (6.7)	1.01 (0.55, 1.83)		1.20 (0.31, 4.71)	
	Moderate	11 (1.5)	9 (4.0)	0.38 (0.15, 0.92)		0.53 (0.09, 3.02)	
	Severe	10 (1.4)	2 (0.9)	Nd		Nd	
Chills	None	656 (91.6)	202 (89.8)	1	0.260	1	0.803
	Mild	35 (4.9)	15 (6.7)	0.72 (0.38, 1.34)		0.89 (0.25, 3.09)	
	Moderate	13 (1.8)	7 (3.1)	0.57 (0.23, 1.45)		0.31 (0.03, 3.17)	
	Severe	12 (1.7)	1 (0.4)	Nd		Nd	
Vomit	None	710 (99.2)	219 (97.3)	1	0.559	1	0.993
	Mild	3 (0.4)	3 (1.3)	0.31 (0.06, 1.54)		Nd	
	Moderate	0 (0.0)	3 (1.3)	Nd		Nd	
	Severe	3 (0.4)	0 (0.0)	Nd		Nd	

		Prevalence of L-AEIs and OR (ID vs. SC)					
Local symptoms	max severity	ID n (%)	SC n (%)	Unadjusted OR ID vs. SC	p-value	Adjusted* OR ID vs. SC	p-value
Redness	None	46 (6.5)	137 (60.9)	1	<.001	1	<0.001
	Mild	168 (23.6)	43 (19.1)	11.63 (7.25, 18.67)		20.84 (6.05, 71.73)	
	Moderate	325 (45.6)	25 (11.1)	38.72 (22.87, 65.54)		47.01 (13.15, 168.0)	
	Severe	173 (24.3)	20 (8.9)	25.76 (14.56, 45.59)		36.37 (9.90, 133.7)	
Induration	None	67 (9.4)	121 (53.8)	1	<.001	1	<0.001
	Mild	264 (37.1)	51 (22.7)	9.35 (6.12, 14.27)		10.84 (4.11, 28.57)	
	Moderate	281 (39.5)	36 (16.0)	14.10 (8.92, 22.28)		12.95 (4.55, 36.83)	
	Severe	100 (14.0)	17 (7.6)	10.62 (5.86, 19.25)		14.20 (4.28, 47.14)	
Pain	None	257 (36.1)	60 (26.7)	1	0.057	1	<0.001
	Mild	266 (37.4)	90 (40.0)	0.69 (0.48, 1.00)		0.21 (0.10, 0.48)	
	Moderate	147 (20.6)	58 (25.8)	0.59 (0.39, 0.90)		0.09 (0.03, 0.26)	
	Severe	42 (5.9)	17 (7.6)	0.58 (0.31, 1.08)		0.37 (0.09, 1.45)	

* Adjusted for age and HIV status; 95 CI: 95% Confidence Interval; Nd: not determined